<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="107439">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01727063</url>
  </required_header>
  <id_info>
    <org_study_id>EMRTCC-ISQ2</org_study_id>
    <nct_id>NCT01727063</nct_id>
  </id_info>
  <brief_title>Cell Therapy in Severe Chronic Ischemic Heart Disease</brief_title>
  <acronym>MiHeart</acronym>
  <official_title>A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy of Intramyocardial Injection of Autologous Bone-Marrow Cells in Patients With Severe, Chronic Ischemic Heart Disease Undergoing Coronary Bypass Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ministry of Health, Brazil</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ministry of Health, Brazil</source>
  <oversight_info>
    <authority>Brazil: National Committee of Ethics in Research</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients with advanced coronary artery disease usually undergo incomplete myocardial
      revascularization due to the extension and diffuseness of the disease, with very poor distal
      arterial beds unsuitable for direct revascularization.

      This study was designed to test the hypothesis that direct, intramyocardial injection of
      autologous bone marrow cells may further improve myocardial perfusion  in patients
      undergoing incomplete bypass surgery.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      All eligible patients will undergo coronary artery bypass grafting (CABG) and, in previously
      identified areas of viable, ischemic myocardium unsuitable for direct revascularization, be
      randomized to either placebo (saline) or intramyocardial injection of bone marrow-derived
      cells (BMC) during surgery.

      During follow-up, myocardial perfusion assessment will be performed to determine the
      improvement in treated areas compared to non-treated segments.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2006</start_date>
  <completion_date type="Anticipated">July 2013</completion_date>
  <primary_completion_date type="Anticipated">July 2013</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Increase in myocardial perfusion</measure>
    <time_frame>1, 6 and 12 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Patients will undergo myocardial perfusion assessment by MRI during pharmacological stress with adenosine or dipyridamole. Alternatively, cardiac scintigraphy can be used in patients with contra-indications to MRI.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Improvement in LV function</measure>
    <time_frame>1, 6 and 12 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>LV function (global and regional) will be assessed by MRI.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Improvement in angina functional class</measure>
    <time_frame>1, 6 and 12 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Angina functional class will be determined using the Canadian Cardiovascular Society classification.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Chronic Ischemic Heart Disease</condition>
  <condition>Coronary Artery Disease</condition>
  <condition>Angina Pectoris</condition>
  <arm_group>
    <arm_group_label>Cell Therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intramyocardial injection of autologous bone marrow-derived cells</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Saline injection</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Cell Therapy</intervention_name>
    <description>Intramyocardial injection of autologous bone marrow-derived cells</description>
    <arm_group_label>Cell Therapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  symptoms of angina or angina equivalent

          -  documented coronary artery disease (invasive angiography)

          -  documented myocardial ischemia (stress echo, cardiac scintigraphy, or MRI)

          -  unsuitable for complete myocardial revascularization (PCI or CABG) OR even if a
             complete procedure in feasible, it is anticipated that myocardial perfusion may not
             be restored due to poor distal beds

        Exclusion Criteria:

          -  severe LV dysfunction (EF &lt; 25% on echo)

          -  short life expectacy (below &lt; 1 year)

          -  diagnosis of cancer in the past 5 years

          -  diagnosis of hematological diseases

          -  diagnosis of severe heart disease of other etiologies including valvular heart
             disease, Chagas' disease, etc)

          -  diagnosis of acute coronary syndrome in the past 3 months

          -  diagnosis of chronic kidney disease stage V requiring chronic dialysis
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jose Eduardo Krieger, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Heart Institute</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Carlos Eduardo Rochitte, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Heart Institute</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Meyrielli A Vieira</last_name>
    <phone>+55-11-2661-5000</phone>
    <phone_ext>5377</phone_ext>
    <email>meyri.vieira@incor.usp.br</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Luis Henrique Gowdak, MD, PhD</last_name>
    <phone>+55-11-2661-5000</phone>
    <phone_ext>5929</phone_ext>
    <email>luis.gowdak@incor.usp.br</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Heart Institute</name>
      <address>
        <city>Sao Paulo</city>
        <state>SP</state>
        <zip>05403-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Luis Henrique W Gowdak, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <reference>
    <citation>Tura BR, Martino HF, Gowdak LH, dos Santos RR, Dohmann HF, Krieger JE, Feitosa G, Vilas-Boas F, Oliveira SA, Silva SA, Bozza AZ, Borojevic R, de Carvalho AC. Multicenter randomized trial of cell therapy in cardiopathies - MiHeart Study. Trials. 2007 Jan 18;8:2.</citation>
    <PMID>17233910</PMID>
  </reference>
  <verification_date>November 2012</verification_date>
  <lastchanged_date>November 12, 2012</lastchanged_date>
  <firstreceived_date>November 12, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ministry of Health, Brazil</investigator_affiliation>
    <investigator_full_name>Dr. Lu√≠s Henrique W. Gowdak</investigator_full_name>
    <investigator_title>Clinical Coordinator</investigator_title>
  </responsible_party>
  <keyword>Chronic ischemic heart disease</keyword>
  <keyword>Coronary artery disease</keyword>
  <keyword>Angina pectoris</keyword>
  <keyword>Myocardial ischemia</keyword>
  <keyword>Cardiac surgery</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Angina Pectoris</mesh_term>
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
    <mesh_term>Heart Diseases</mesh_term>
    <mesh_term>Ischemia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
